Executive summary
What this whitepaper covers
As cybersecurity threats against connected medical devices continue to rise, both regulators and manufacturers face the challenge of balancing process-driven oversight with product-level technical safeguards.
This whitepaper examines postmarket cybersecurity disclosures through the lens of the FDA Postmarket Management Guidance and NIST Cybersecurity Framework (NIST-CSF), revealing how many vulnerabilities remain unaddressed — and how Medcrypt’s technology could mitigate the majority of them. Using real-world data from the ICS-CERT advisory database, the paper quantifies Medcrypt’s impact on reducing vulnerability exposure and supporting proactive threat detection across the medical device ecosystem.
Why it matters
The regulatory and product context
FDA guidance now expects manufacturers to not only design secure products but also manage risk throughout the device lifecycle. Yet, between 2013 and 2018, only a small fraction of the NIST-CSF cybersecurity subcategories were referenced in medical device vulnerability disclosures. The findings highlight a critical gap: while 72% of the FDA’s recommendations address process interventions, 28% require product solutions — areas where software-based tools like Medcrypt can have the most direct impact.
This whitepaper helps medical device leaders understand:
- Where current postmarket cybersecurity efforts fall short
- How FDA and NIST-CSF frameworks intersect
- Which vulnerabilities can be technically mitigated through embedded security solutions
Key insights
What you’ll take away
- Only 12% of NIST-CSF cybersecurity subcategories have been represented in historical vulnerability disclosures, leaving major blind spots.
- Medcrypt’s capabilities address 80% of the technical subcategories and could have prevented 76% of known vulnerabilities.
- FDA’s focus on both process and product interventions underscores the need for embedded, proactive cybersecurity solutions.
- Threat sharing, forensic monitoring, and data encryption are becoming regulatory expectations, not optional features.
Who should read this
- Engineering and product development teams seeking to strengthen postmarket cybersecurity posture
- Regulatory and QA/RA professionals aligning with FDA postmarket and 524B requirements
- CISOs and cybersecurity program leaders evaluating secure design and detection frameworks
- Executives and compliance officers driving organizational readiness and market trust
